LOGC:NSD-Contextlogic Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 6.8

Change

+0.12 (+1.80)%

Market Cap

N/A

Volume

0.18M

Analyst Target

USD 22.00
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.47 (+0.61%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

+2.21 (+0.31%)

USD 84.94B
ARGX argenx NV ADR

+2.05 (+0.33%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

-0.75 (-0.31%)

USD 31.66B
BGNE BeiGene Ltd

+3.06 (+1.68%)

USD 20.24B
UTHR United Therapeutics Corporatio..

+3.23 (+0.90%)

USD 16.18B
MRNA Moderna Inc

+0.16 (+0.40%)

USD 16.10B
RPRX Royalty Pharma Plc

+0.17 (+0.67%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.28 (+1.47%)

USD 13.67B
INCY Incyte Corporation

-0.35 (-0.50%)

USD 13.52B

ETFs Containing LOGC

INKM SPDR® SSgA Income Alloca.. 0.00 % 0.39 %

-0.46 (0.21%)

USD 0.07B
FISR SPDR® SSGA Fixed Income .. 0.00 % 0.00 %

+0.05 (+0.21%)

USD 0.29B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -96.80% 17% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -96.80% 17% F 6% D-
Average Annual (5 Year Horizon)  
Capital Gain 64.48% 80% B- 89% A-
Dividend Return 64.48% 80% B- 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 166.97% 27% F 14% F
Risk Adjusted Return 38.61% 89% A- 69% C-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.